Welcome to our dedicated page for Anavex Life Scie news (Ticker: AVXL), a resource for investors and traders seeking the latest updates and insights on Anavex Life Scie stock.
Anavex Life Sciences Corp. reports developments as a clinical-stage biopharmaceutical company focused on central nervous system disorders, including Alzheimer’s disease, Parkinson’s disease, schizophrenia, Rett syndrome, and other neurodevelopmental, neurodegenerative, and rare diseases. Company news frequently centers on blarcamesine, its orally administered lead candidate, along with precision-medicine analyses using genomic and biomarker data.
Recurring updates include clinical and preclinical data presentations, scientific findings related to autophagy, synaptic dysfunction, SIGMAR1 biology, and disease mechanisms, as well as regulatory communications with the FDA and EMA. News also covers financial results, healthcare conference participation, board composition, executive leadership changes, and other corporate governance matters.
Anavex Life Sciences Corp. (Nasdaq: AVXL) will release its fiscal year 2022 financial results on November 28, 2022, at 8:30 am ET. Following the results, a conference call will be held to discuss the findings and the company's growth strategy. Anavex focuses on developing therapeutics for neurodegenerative disorders, including Alzheimer’s and Parkinson’s diseases. Its lead candidate, ANAVEX®2-73, has completed several clinical trials, showing promise in treating these conditions. A webcast of the call will be available on their website.
Anavex Life Sciences Corp. (Nasdaq: AVXL) announced that CEO Christopher U Missling, PhD, will present at the Guggenheim 4th Annual Immunology and Neurology Conference on November 14, 2022, at 11:20 AM ET, in New York. The conference will focus on their development of therapeutics for neurodegenerative diseases such as Alzheimer's and Parkinson's. A live webcast will be accessible through their website, with an archived version available later. Anavex's lead drug candidate, ANAVEX®2-73, shows promise in treating Alzheimer's and other CNS disorders.
Anavex Life Sciences Corp. (Nasdaq: AVXL) has received Orphan Drug Designation from the U.S. FDA for ANAVEX®2-73 (blarcamesine) aimed at treating Fragile X syndrome (FXS), which affects an estimated 62,500 individuals in the U.S. and over 1 million globally. This designation allows for development incentives, including tax credits and marketing exclusivity. The CEO emphasized the potential for ANAVEX®2-73 to significantly aid the FXS community, while the company continues its late-stage clinical trials across various neurological disorders.
Anavex Life Sciences Corp. (Nasdaq: AVXL) announced the presentation of Phase 2b/3 data for ANAVEX®2-73 (blarcamesine) aimed at treating Early Alzheimer's Disease, scheduled for December 1, 2022, at the CTAD Congress in San Francisco. A/Prof. Stephen Macfarlane will present the findings, which will also be published in a peer-reviewed journal. ANAVEX®2-73 is recognized as a significant therapeutic option targeting the sigma-1 receptor, showing promise from prior clinical trials in Alzheimer's and other CNS disorders. The economic burden of Alzheimer's is projected to exceed $1 trillion as the population ages.
Anavex Life Sciences Corp. (Nasdaq: AVXL) announced the issuance of U.S. Patent No. 11,446,275, enhancing its intellectual property for ANAVEX®2-73 (blarcamesine). This patent covers treatment methods for conditions related to methyl-CpG binding protein 2 defects, including Rett syndrome and autism, ensuring protection until at least 2037. Anavex has recently secured multiple patents supporting its drug portfolio, demonstrating commitment to innovation in therapies for neurodegenerative disorders. ANAVEX®2-73 has shown positive results in Phase 2 and Phase 3 trials.
Anavex Life Sciences Corp. (Nasdaq: AVXL) announced a new peer-reviewed publication in Science Translational Medicine, highlighting the role of sigma-1 receptor (SIGMAR1) in early Alzheimer's disease. The study suggests SIGMAR1 activation may serve as a compensatory mechanism, helping to restore neural balance and promote neuroplasticity. Top line results from the Phase 2b/3 study of ANAVEX®2-73 for Alzheimer's are expected in fall 2022. This research underscores the need for treatments targeting multiple pathways in Alzheimer's disease to effectively slow progression and improve cognitive function.
Anavex Life Sciences Corp. (AVXL) reported its fiscal Q3 2022 financial results, highlighting a net loss of $12.4 million, or $0.16 per share, compared to a loss of $10.2 million, or $0.14 per share a year prior. Cash reserves stand at $153.2 million. The company is advancing its clinical pipeline, focusing on therapies for neurodegenerative diseases, with anticipated data readouts for ANAVEX®2-73 in Alzheimer’s and Rett syndrome by year-end. The economic burden of Alzheimer’s disease is significant, projected to exceed $1 trillion in healthcare costs as the population ages.
Anavex Life Sciences Corp. (Nasdaq: AVXL) announces a conference call on August 9, 2022, at 4:30 PM ET to discuss its financial results for the quarter ending June 30, 2022, and updates on its growth strategy. The call will be accessible via Anavex's website. The company specializes in therapeutics for neurodegenerative disorders, with its lead drug candidate, ANAVEX®2-73, showing promise in various trials for conditions such as Alzheimer’s and Parkinson’s disease.
Anavex Life Sciences Corp. (Nasdaq: AVXL) announced promising results for its drug candidate ANAVEX®3-71 at the Alzheimer’s Association International Conference. The study showed a significant decrease in amyloid beta deposition and reduced inflammatory responses in transgenic rat models of Alzheimer’s disease. Key behavioral tests demonstrated that ANAVEX®3-71 reversed cognitive deficits, with statistical significance (p ≤ 0.01). This data supports Anavex’s Precision Medicine platform and raises confidence in addressing neurodegenerative diseases.
Anavex Life Sciences Corp. (Nasdaq: AVXL) announced significant results from their Phase 2 PDD study of ANAVEX®2-73 at the AAIC conference. The study demonstrated the restoration of expression levels of neurodegenerative genes associated with Alzheimer's and Parkinson's diseases (p0.005). Conducted on 132 patients, the trial exhibited dose-dependent improvements in cognitive and motor assessments. Dr. Jaime Kulisevsky highlighted the study as a novel exploration of therapeutic effects in Parkinson’s disease dementia, marking ANAVEX®2-73 as a potential breakthrough treatment.